FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W67559354> ?p ?o ?g. }

• W67559354 endingPage "16126" @default.
• W67559354 startingPage "16126" @default.
• W67559354 abstract "16126 Background: Docetaxel (D) has been shown to prolong survival in men with hormone refractory prostate cancer (HRPC). However, this treatment is not without side effects and asymptomatic patients may not wish to pursue toxic treatment if they would not be expected to obtain a survival improvement. A prostate specific antigen (PSA) reduction of ≥50% from baseline 90 days post- treatment has been identified as a potential surrogate for survival benefit from D, but if an earlier surrogate could be found, it would allow patients who would not benefit from treatment to stop sooner. PSA doubling time (PSADT) has been identified as a potential surrogate marker for survival in patients at risk for progression after local curative treatment or HRPC. We propose that PSA half-life (PSAHL), may aid in predicting survival patients with HRPC treated with D. Methods: A retrospective chart review of 154 patients with HRPC treated from January 2000 to May 2006 was performed. All patients had metastatic HRPC and received at least one cycle of D. PSA response was calculated and PSAHL was determined for patients with any PSA decline from baseline at 42 and 90 days after starting D. Patients were optimally stratified using the log-rank chi-square statistic and Kaplan-Meier curves were used to estimate overall survival. Results: During the follow-up period, 54% of patients died and 71% experienced biochemical progression. Median overall survival (OS) from initiation of D was 16 months. OS was improved for patients achieving a ≥50% reduction in PSA at 90 days compared to those who did not (22 versus 16 months), but no difference in OS was noted for any stratification based on PSA alone or PSAHL at 42 days. Optimal 90 day PSAHL stratification was obtained at >70 days (OS 15 versus 25 months). Survival benefit found for PSAHL > 70 days remained following multivariate analysis [HR 11.84 (2.95–47.50)]. Conclusions: A 90 day PSAHL > 70 days was associated with a significant OS advantage of 10 months in patients receiving D treatment for HRPC. No survival difference could be predicted by PSA response or PSAHL at 42 days post chemotherapy initiation. No significant financial relationships to disclose." @default.
• W67559354 created "2016-06-24" @default.
• W67559354 creator A5057439948 @default.
• W67559354 creator A5061626918 @default.
• W67559354 creator A5075793247 @default.
• W67559354 date "2008-05-20" @default.
• W67559354 modified "2023-09-25" @default.
• W67559354 title "Prediction of survival benefit from docetaxel chemotherapy with PSA response and PSA half-life in men with metastatic hormone refractory prostate cancer" @default.
• W67559354 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.16126" @default.
• W67559354 hasPublicationYear "2008" @default.
• W67559354 type Work @default.
• W67559354 sameAs 67559354 @default.
• W67559354 citedByCount "1" @default.
• W67559354 countsByYear W675593542014 @default.
• W67559354 crossrefType "journal-article" @default.
• W67559354 hasAuthorship W67559354A5057439948 @default.
• W67559354 hasAuthorship W67559354A5061626918 @default.
• W67559354 hasAuthorship W67559354A5075793247 @default.
• W67559354 hasConcept C10515644 @default.
• W67559354 hasConcept C121608353 @default.
• W67559354 hasConcept C126322002 @default.
• W67559354 hasConcept C126894567 @default.
• W67559354 hasConcept C141071460 @default.
• W67559354 hasConcept C141341695 @default.
• W67559354 hasConcept C143998085 @default.
• W67559354 hasConcept C2776694085 @default.
• W67559354 hasConcept C2777910003 @default.
• W67559354 hasConcept C2780192828 @default.
• W67559354 hasConcept C2780739268 @default.
• W67559354 hasConcept C2781190966 @default.
• W67559354 hasConcept C2781406297 @default.
• W67559354 hasConcept C71924100 @default.
• W67559354 hasConceptScore W67559354C10515644 @default.
• W67559354 hasConceptScore W67559354C121608353 @default.
• W67559354 hasConceptScore W67559354C126322002 @default.
• W67559354 hasConceptScore W67559354C126894567 @default.
• W67559354 hasConceptScore W67559354C141071460 @default.
• W67559354 hasConceptScore W67559354C141341695 @default.
• W67559354 hasConceptScore W67559354C143998085 @default.
• W67559354 hasConceptScore W67559354C2776694085 @default.
• W67559354 hasConceptScore W67559354C2777910003 @default.
• W67559354 hasConceptScore W67559354C2780192828 @default.
• W67559354 hasConceptScore W67559354C2780739268 @default.
• W67559354 hasConceptScore W67559354C2781190966 @default.
• W67559354 hasConceptScore W67559354C2781406297 @default.
• W67559354 hasConceptScore W67559354C71924100 @default.
• W67559354 hasIssue "15_suppl" @default.
• W67559354 hasLocation W675593541 @default.
• W67559354 hasOpenAccess W67559354 @default.
• W67559354 hasPrimaryLocation W675593541 @default.
• W67559354 hasRelatedWork W1672944621 @default.
• W67559354 hasRelatedWork W1980998207 @default.
• W67559354 hasRelatedWork W2268282789 @default.
• W67559354 hasRelatedWork W2299690226 @default.
• W67559354 hasRelatedWork W2770702948 @default.
• W67559354 hasRelatedWork W2789553788 @default.
• W67559354 hasRelatedWork W2808552915 @default.
• W67559354 hasRelatedWork W3016283493 @default.
• W67559354 hasRelatedWork W3181573761 @default.
• W67559354 hasRelatedWork W3204029969 @default.
• W67559354 hasVolume "26" @default.
• W67559354 isParatext "false" @default.
• W67559354 isRetracted "false" @default.
• W67559354 magId "67559354" @default.
• W67559354 workType "article" @default.